nach oben

Head and Neck Pathology

Erschienen in:

28.09.2022 | Original Paper

Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment

verfasst von: Sajjad Gerdabi, Fatemeh Asadian, Razie Kiani, Bijan Khademi, Mohammad Reza Haghshenas, Nasrollah Erfani

Erschienen in: Head and Neck Pathology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

To investigate the differential expression of PD-1 and PD-L1 in salivary gland tumors (SGTs, malignant and benign subtypes) and determine their association with the clinicopathological characterization of the patients.

Methods

The immunohistochemistry was used to examine PD-1 and PD-L1 expression in specimens from 83 patients with primary SGTs including salivary ductal carcinoma (SDC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (ACC), mucoepidermoid carcinoma (MEC), warthin’s tumors (WT), poleomorphic adenoma (PA) and other subtypes.

Results

The expression of PD-1 in peripheral and central immune cells (ICs) of MEC, and peripheral ICs of ACC was significantly higher than those with AdCC (P = 0.02, P = 0.02, P = 0.03, respectively). Interestingly, the expression of PD-1 was also observed in peripheral and central malignant tumor cells (TCs), particularly in SDC and ACC. Despite no significant difference in PD-L1 expression of TCs among malignant subtypes, the peripheral and central ICs of ACC and MEC were revealed to express PDL-1 significantly more than those with AdCC (P < 0.05). WTs were rich in PD-1/PD-L1 expressing ICs. However, the tumor microenvironment of PA generally had low levels of PD-1/PD-L1 expression. In general, the expression of PD-1 in peripheral and central TCs was found to be significantly higher in malignant tumors than in benign ones (P = 0.002 and P = 0.003, respectively).

Conclusion

The simultaneous presentation of PD-1 and PD-L1 in TCs and ICs of SGTs, their significant association with disease severity as well as the positive correlation between these immune checkpoints may suggest the therapeutic potential of anti-PD-1 and anti-PDL-1 combinational immunotherapy for SGTs.

Żurek M, Rzepakowska A, Jasak K, Niemczyk K. The epidemiology of salivary glands pathologies in adult population over 10 years in poland-cohort study. Int J Environ Res Public Health. 2021. https://doi.org/10.3390/ijerph19010179.CrossRefPubMedPubMedCentral

Carlson ER, Schlieve T. Salivary gland malignancies. Oral Maxillofac Surg Clin North Am. 2019;31:125–44. https://doi.org/10.1016/j.coms.2018.08.007.CrossRefPubMed

Bradley PJ. Classification of salivary gland neoplasms. Adv Otorhinolaryngol. 2016;78:1–8. https://doi.org/10.1159/000442119.CrossRefPubMed

Sowa P, Goroszkiewicz K, Szydelko J, Chechlinska J, Pluta K, Domka W, et al. A review of selected factors of salivary gland tumour formation and malignant transformation. Biomed Res Int. 2018;2018:2897827. https://doi.org/10.1155/2018/2897827.CrossRefPubMedPubMedCentral

Mantravadi AV, Moore MG, Rassekh CH. AHNS series: do you know your guidelines? Diagnosis and management of salivary gland tumors. Head Neck. 2019;41:269–80. https://doi.org/10.1002/hed.25499.CrossRefPubMed

Yu G, Peng X. Conservative and functional surgery in the treatment of salivary gland tumours. Int J Oral Sci. 2019;11:22. https://doi.org/10.1038/s41368-019-0059-9.CrossRefPubMedPubMedCentral

Amini A, Waxweiler TV, Brower JV, Jones BL, McDermott JD, Raben D, et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the national cancer data base. JAMA Otolaryngol Head Neck Surg. 2016;142:1100–10. https://doi.org/10.1001/jamaoto.2016.2168.CrossRefPubMed

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–68. https://doi.org/10.1038/s41577-020-0306-5.CrossRefPubMedPubMedCentral

Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12030738.CrossRefPubMed

10.

Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol. 2017;28:2539–46. https://doi.org/10.1093/annonc/mdx399.CrossRefPubMedPubMedCentral

11.

Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, et al. Genomic landscape of salivary gland tumors. Oncotarget. 2015;6:25631–45. https://doi.org/10.18632/oncotarget.4554.CrossRefPubMedPubMedCentral

12.

Vital D, Ikenberg K, Moch H, Rössle M, Huber GF. The expression of PD-L1 in salivary gland carcinomas. Sci Rep. 2019;9:12724. https://doi.org/10.1038/s41598-019-49215-9.CrossRefPubMedPubMedCentral

13.

Sato F, Ono T, Kawahara A, Matsuo K, Kondo R, Sato K, et al. Prognostic value of tumor proportion score in salivary gland carcinoma. Laryngoscope. 2021;131:E1481–8. https://doi.org/10.1002/lary.29120.CrossRefPubMed

14.

Kuchar M, Strizova Z, Capkova L, Komarc M, Skrivan J, Bartunkova J, et al. The periphery of salivary gland carcinoma tumors reveals a PD-L1/PD-1 biomarker niche for the evaluation of disease severity and tumor-immune system interplay. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9020097.CrossRefPubMedPubMedCentral

15.

Porcheri C, Meisel CT, Mitsiadis TA. Molecular and cellular modelling of salivary gland tumors open new landscapes in diagnosis and treatment. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12113107.CrossRefPubMedPubMedCentral

16.

Witte HM, Gebauer N, Lappöhn D, Umathum VG, Riecke A, Arndt A, et al. Prognostic impact of PD-L1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12040873.CrossRefPubMedPubMedCentral

17.

Fang Q, Wu Y, Du W, Zhang X, Chen D. Incidence and prognostic significance of PD-L1 expression in high-grade salivary gland carcinoma. Front Oncol. 2021;11:701181. https://doi.org/10.3389/fonc.2021.701181.CrossRefPubMedPubMedCentral

18.

Kuzenko YV, Romanuk AM, Dyachenko OO, Hudymenko O. Pathogenesis of warthin’s tumors. Interv Med Appl Sci. 2016;8:41–8. https://doi.org/10.1556/1646.8.2016.2.2.CrossRefPubMedPubMedCentral

19.

Haghshenas MR, Khademi B, Faghih Z, Ghaderi A, Erfani N. Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors. Immunol Lett. 2015;164:109–16. https://doi.org/10.1016/j.imlet.2015.02.008.CrossRefPubMed

20.

Haghshenas MR, Khademi B, Ashraf MJ, Ghaderi A, Erfani N. Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors. Oral Dis. 2016;22:566–72. https://doi.org/10.1111/odi.12496.CrossRefPubMed

21.

Haghshenas MR, Ghaderi H, Daneste H, Ghaderi A. Immunological and biological dissection of normal and tumoral salivary glands. Int Rev Immunol. 2021. https://doi.org/10.1080/08830185.2021.1958806.CrossRefPubMed

22.

Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci USA. 2020;117:6640–50. https://doi.org/10.1073/pnas.1921445117.CrossRefPubMedPubMedCentral

23.

Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology. 2017;66:1920–33. https://doi.org/10.1002/hep.29360.CrossRefPubMed

24.

Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242–56. https://doi.org/10.1016/j.cell.2015.08.052.CrossRefPubMedPubMedCentral

25.

Sakai M, Fukumoto M, Ikai K, Ono Minagi H, Inagaki S, Kogo M, et al. Role of the mTOR signalling pathway in salivary gland development. Febs j. 2019;286:3701–17. https://doi.org/10.1111/febs.14937.CrossRefPubMed

26.

Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res. 2010;70:9143–52. https://doi.org/10.1158/0008-5472.Can-10-1758.CrossRefPubMed

27.

Sato T, Maeta T, Abe R, Yamada H, Ishida K, Yashima-Abo A, et al. Successful treatment with nivolumab in a patient with metastatic salivary duct carcinoma. Case Rep Oncol. 2021;14:343–6. https://doi.org/10.1159/000512060.CrossRefPubMedPubMedCentral

28.

Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther. 2017;10:2983–92. https://doi.org/10.2147/ott.S134589.CrossRefPubMedPubMedCentral

29.

Mosconi C, de Arruda JAA, de Farias ACR, Oliveira GAQ, de Paula HM, Fonseca FP, et al. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol. 2019;88:95–101. https://doi.org/10.1016/j.oraloncology.2018.11.028.CrossRefPubMed

30.

Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72–81. https://doi.org/10.1016/j.canlet.2019.10.013.CrossRefPubMed

31.

Tang YL, Fan YL, Jiang J, Li KD, Zheng M, Chen W, et al. C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget. 2014;5:1491–501. https://doi.org/10.18632/oncotarget.1606.CrossRefPubMedPubMedCentral

32.

Enescu AS, Mărgăritescu CL, Crăiţoiu MM, Enescu A, Crăiţoiu Ş. The involvement of growth differentiation factor 5 (GDF5) and aggrecan in the epithelial-mesenchymal transition of salivary gland pleomorphic adenoma. Rom J Morphol Embryol. 2013;54:969–76.PubMed

33.

Hellquist H, Paiva-Correia A, Vander Poorten V, Quer M, Hernandez-Prera JC, Andreasen S, et al. Analysis of the clinical relevance of histological classification of benign epithelial salivary gland tumours. Adv Ther. 2019;36:1950–74. https://doi.org/10.1007/s12325-019-01007-3.CrossRefPubMedPubMedCentral

34.

Chin KW, Billings KR, Ishiyama A, Wang MB, Wackym PA. Characterization of lymphocyte subpopulations in warthin’s tumor. Laryngoscope. 1995;105:928–33. https://doi.org/10.1288/00005537-199509000-00011.CrossRefPubMed

35.

O’Neill ID. New insights into the nature of warthin’s tumour. J Oral Pathol Med. 2009;38:145–9. https://doi.org/10.1111/j.1600-0714.2008.00676.x.CrossRefPubMed

36.

Triantafyllou A, Thompson LD, Devaney KO, Bell D, Hunt JL, Rinaldo A, et al. Functional histology of salivary gland pleomorphic adenoma: an appraisal. Head Neck Pathol. 2015;9:387–404. https://doi.org/10.1007/s12105-014-0581-1.CrossRefPubMed

37.

Brodetskyi IS, Dyadyk OO, Myroshnychenko MS, Zaritska VI. Morphological characteristics of pleomorphic adenomas of salivary glands (analysis of the surgical material). Wiad Lek. 2020;73:2339–44.CrossRefPubMed

38.

Hiss S, Eckstein M, Segschneider P, Mantsopoulos K, Iro H, Hartmann A, et al. Tumour-infiltrating lymphocytes (TILs) and PD-L1 expression correlate with lymph node metastasis, high-grade transformation and shorter metastasis-free survival in patients with acinic cell carcinoma (AciCC) of the salivary glands. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13050965.CrossRefPubMed

39.

Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer. 2018;18:156. https://doi.org/10.1186/s12885-018-4069-3.CrossRefPubMedPubMedCentral

40.

Strizova Z, Taborska P, Stakheev D, Partlová S, Havlova K, Vesely S, et al. NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma. Urol Oncol. 2019;37:503–9. https://doi.org/10.1016/j.urolonc.2019.03.014.CrossRefPubMed

41.

Strizova Z, Snajdauf M, Stakheev D, Taborska P, Vachtenheim J Jr, Biskup J, et al. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients. J Cancer Res Clin Oncol. 2020;146:1979–92. https://doi.org/10.1007/s00432-020-03258-y.CrossRefPubMed

42.

Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res. 2020;26:837–45. https://doi.org/10.1158/1078-0432.Ccr-19-2214.CrossRefPubMed

43.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol. 2018;41:1083–8. https://doi.org/10.1097/coc.0000000000000429.CrossRefPubMedPubMedCentral

44.

Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015;32:86. https://doi.org/10.1007/s12032-015-0501-6.CrossRefPubMed

45.

Yin H, Tang Y, Guo Y, Wen S. Immune microenvironment of thyroid cancer. J Cancer. 2020;11:4884–96. https://doi.org/10.7150/jca.44506.CrossRefPubMedPubMedCentral

46.

Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, et al. A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. Int J Radiat Oncol Biol Phys. 2021;109:134–44. https://doi.org/10.1016/j.ijrobp.2020.08.018.CrossRefPubMed

47.

Giraldo NA, Becht E, Pagès F, Skliris G, Verkarre V, Vano Y, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21:3031–40. https://doi.org/10.1158/1078-0432.Ccr-14-2926.CrossRefPubMed

48.

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34. https://doi.org/10.1038/nrclinonc.2017.101.CrossRefPubMed

Titel: Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment
verfasst von: Sajjad Gerdabi
Fatemeh Asadian
Razie Kiani
Bijan Khademi
Mohammad Reza Haghshenas
Nasrollah Erfani
Publikationsdatum: 28.09.2022
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 1/2023
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-022-01486-x

Springer Medizin

Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Top 10 Differential Diagnoses for Desmoplastic Melanoma

Lymphomas Affecting the Sublingual Glands: A Clinicopathological Study

Top Ten Oncocytic Head and Neck Lesions to Contemplate

A 10-Year Review of Intraoral Salivary Gland Tumor Diagnoses: Diagnostic Challenges and Inter-Observer Agreement

Adenoid Ameloblastoma Versus Dentinogenic Ghost Cell Tumor

Lingual Alveolar Soft Part Sarcoma in a 78-Year-Old Woman: A Case Report and Comprehensive Review of the Literature from 1952 to 2022

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie